Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.
← catalyst calendarNCT05592002 · readout ≤ 42 d
Sponsored by Nyxoah S.A. (industry) · NYXH.BR — their whole pipeline →. With Nyxoah Inc..
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
124estimated
Sites
16
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-28 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2022-10-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Sleep Apnea, Obstructive
Intervention
- Device: Genio System — also filed as Genio System 2.0
Primary outcome
what the primary-completion date above is the date OFPrimary Effectiveness Endpoint
measured The duration of the study is expected to be approximately 4.5 years.
Permalink · NYXH.BR's whole pipeline · Catalyst calendar · Every registered study · What changed